{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ErbB+Receptors&page=2", "query": { "condition": "ErbB Receptors", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ErbB+Receptors&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-05-22T09:05:32.385Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06186401", "title": "Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "EGFR Gene Mutation", "Glioblastoma", "MGMT-Unmethylated Glioblastoma", "Recurrent Glioblastoma" ], "interventions": [ { "name": "E-SYNC T Cells", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide (non-investigational)", "type": "DRUG" }, { "name": "Fludarabine (non-investigational)", "type": "DRUG" }, { "name": "Leukapheresis", "type": "PROCEDURE" }, { "name": "Surgical resection", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE" ], "sponsor": "Hideho Okada, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2024-04-30", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-03-16", "last_synced_at": "2026-05-22T09:05:32.385Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06186401" }, { "nct_id": "NCT03734029", "title": "Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Trastuzumab deruxtecan (DS-8201a)", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 557, "start_date": "2018-12-27", "completion_date": "2026-08-01", "has_results": true, "last_update_posted_date": "2025-10-06", "last_synced_at": "2026-05-22T09:05:32.385Z", "location_count": 38, "location_summary": "Chandler, Arizona • Gilbert, Arizona • Goodyear, Arizona + 31 more", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Goodyear", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03734029" }, { "nct_id": "NCT06760637", "title": "Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "PF-07220060", "type": "DRUG" }, { "name": "letrozole", "type": "DRUG" }, { "name": "abemaciclib", "type": "DRUG" }, { "name": "palbociclib", "type": "DRUG" }, { "name": "ribociclib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1035, "start_date": "2025-01-06", "completion_date": "2037-12-29", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-05-22T09:05:32.385Z", "location_count": 218, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 135 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06760637" }, { "nct_id": "NCT06147037", "title": "A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "Metastatic Colorectal Carcinoma", "Head and Neck Squamous Cell Carcinoma", "Non-small Cell Lung Cancer", "Pancreatic Ductal Adenocarcinoma", "Gastric Cancer", "Renal Cell Carcinoma" ], "interventions": [ { "name": "FPI-2053", "type": "DRUG" }, { "name": "[111In]-FPI-2107", "type": "DRUG" }, { "name": "[225Ac]-FPI-2068", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 70, "start_date": "2024-07-31", "completion_date": "2028-05-12", "has_results": false, "last_update_posted_date": "2026-04-28", "last_synced_at": "2026-05-22T09:05:32.385Z", "location_count": 11, "location_summary": "Irvine, California • Palo Alto, California • Santa Monica, California + 8 more", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT06147037" }, { "nct_id": "NCT04147819", "title": "A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancers With HER2 Expression" ], "interventions": [ { "name": "BAY2701439", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2020-07-02", "completion_date": "2023-09-26", "has_results": false, "last_update_posted_date": "2024-09-27", "last_synced_at": "2026-05-22T09:05:32.385Z", "location_count": 4, "location_summary": "Baltimore, Maryland • St Louis, Missouri • New York, New York + 1 more", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04147819" }, { "nct_id": "NCT06452277", "title": "A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Advanced Non-small Cell Lung Cancer", "HER2 Mutation" ], "interventions": [ { "name": "Sevabertinib", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 444, "start_date": "2024-08-28", "completion_date": "2029-06-27", "has_results": false, "last_update_posted_date": "2026-05-18", "last_synced_at": "2026-05-22T09:05:32.385Z", "location_count": 27, "location_summary": "Newport Beach, California • San Diego, California • San Francisco, California + 21 more", "locations": [ { "city": "Newport Beach", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06452277" }, { "nct_id": "NCT04498481", "title": "TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1, "start_date": "2018-03-01", "completion_date": "2018-07-01", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-05-22T09:05:32.385Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04498481" }, { "nct_id": "NCT02684032", "title": "A Study To Assess The Tolerability And Clinical Activity Of Gedatolisib In Combination With Palbociclib/Letrozole Or Palbociclib/Fulvestrant In Women With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Gedatolisib", "type": "DRUG" }, { "name": "Palbociclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celcuity Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 141, "start_date": "2016-06-14", "completion_date": "2022-01-19", "has_results": false, "last_update_posted_date": "2022-07-27", "last_synced_at": "2026-05-22T09:05:32.385Z", "location_count": 41, "location_summary": "Birmingham, Alabama • Corona, California • Fountain Valley, California + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Corona", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02684032" }, { "nct_id": "NCT04460898", "title": "RW Treatment Patterns and Outcomes in Postmenopausal HR+/HER2- mBC Patients Treated With Palbociclib Plus Letrozole as Initial Endocrine Therapy at Community Oncology Practices in the U.S.", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Breast Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 195, "start_date": "2019-01-04", "completion_date": "2019-06-24", "has_results": true, "last_update_posted_date": "2024-10-04", "last_synced_at": "2026-05-22T09:05:32.385Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04460898" }, { "nct_id": "NCT06139107", "title": "RADIANT: Pre-op Radiation With Abemaciclib and Letrozole", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Abemaciclib", "type": "DRUG" }, { "name": "Letrozole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mridula George, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "FEMALE", "summary": "60 Years and older · Female only" }, "enrollment_count": 15, "start_date": "2024-08-22", "completion_date": "2032-09-30", "has_results": false, "last_update_posted_date": "2025-11-14", "last_synced_at": "2026-05-22T09:05:32.385Z", "location_count": 4, "location_summary": "Belleville, New Jersey • Livingston, New Jersey • New Brunswick, New Jersey + 1 more", "locations": [ { "city": "Belleville", "state": "New Jersey" }, { "city": "Livingston", "state": "New Jersey" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Somerville", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT06139107" } ] }